GSK sells Innoviva stake back to company for $392m

GlaxoSmithKline (GSK) is selling its entire stake in Innoviva back to Innoviva for approximately $392 million.

Following settlement of the transaction, GSK will no longer hold any Innoviva stock.

The terms of GSK’s long-standing and successful respiratory collaboration with Innoviva remain unchanged.

Under this agreement GSK pays royalties to Innoviva on Trelegy Ellipta, Relvar/Breo Ellipta and Anoro Ellipta.

In 2020, sales of Trelegy Ellipta were £819 million; Relvar/Breo Ellipta sales were £1.1 billion, and Anoro Ellipta were £547 million.

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Related news